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The incidence of AD is increasing in parallel with the increase in life expectancy. At the same time the prevalence of metabolic
syndrome and obesity is reaching epidemic proportions in western populations. Stress is one of the major inducers of visceral fat
and obesity development, underlying accelerated aging processes. Adipose tissue is at present considered as an active endocrine
organ, producing important mediators involved in metabolism regulation as well as in inﬂammatory mechanisms. Insulin and
leptin resistance has been related to the dysregulation of energy balance and to the induction of a chronic inﬂammatory status
which have been recognized as important cofactors in cognitive impairment and AD initiation and progression. The aim of this
paper is to disclose the correlation between the onset and progression of AD and the stress-induced changes in lifestyle, leading
to overnutrition and reduced physical activity, ending with metabolic syndrome and obesity. The involved molecular mechanisms
will be brieﬂy discussed, and advisable guide lines for the prevention of AD through lifestyle modiﬁcations will be proposed.
1. Alzheimer’s Disease (AD)
Alzheimer’s disease (AD) is the most common cause of
dementia, accounting for 60–80% of cases, although there
is growing awareness that AD is often confused with other
causes of dementia. According to estimates by 2006, approx-
imately 33.9million people worldwide have AD [1], and
Alzheimer’s Association estimates 5 to 3 million people in
the US have the disease [2]. It is foreseen that the prevalence
will nearly triple [1] or increase from three to four times,
according to other studies, in the next 40 years due to demo-
graphic changes and a longer life expectancy [3]. Among
the sixty year olds, those who show a higher prevalence are
North Americans (6.4%) and Western Europeans (5.4%).
For the rest there is 4.9% in Latin America. It is to outline
that incidence is likely to increase in proportion to the
aging population, which by 2030 would increase by 250%
in industrialized countries. Previous data show that rates of
dementia increase exponentially with age [4]. The incidence
of dementia doubles every 5 years, from 0.66/100 persons
aged 70 to 74 years to 11.30/100 persons for those aged 90
or more.
A bulk of studies has provided evidence to support the
role of obesity as a risk factor for AD development and
the possible role of psychosocial factors (e.g., professional
achievements, stimulant mental activities, social engage-
ment, and physical activity) as protective factors.
1.1. Stress in Modern Societies That Inﬂuences AD. “Lifestyle
has dramatically changed in modern societies and social
psychological stress is ubiquitous and universally pervasive.
In modern life, statistics show powerful eﬀects of early-life
stress, concurrent chronic stress, and socioeconomic status
with sociopolitical system have a potent eﬀect on the burden
of chronic disease” [5].
Increasing evidence has been accumulating about the
role of stress as an important challenge to the onset and
progression of AD [6]. The heterogeneous nature of AD is2 Current Gerontology and Geriatrics Research
only partly explained by the brain’s propensity to accumulate
aberrantly processed, misfolded, and aggregated oligomeric
structural proteins, including amyloid-β peptides and hyper-
phosphorylated tau.
2. Globesity
Obesity and the metabolic syndrome are challenging public
health issues since their prevalence in Western populations
has reached epidemic proportions. In 1997 the World Health
Organization (WHO) stated that “...obesity should now be
regarded as one of the greatest neglected public health prob-
lems of our time....” During the last four decades the world
has experienced an epidemic of overweight individuals and
the WHO has predicted a “globesity epidemic” with more
than1billionadultsbeingoverweightandatleast300million
of these being clinically obese [7]. In the United States
approximately65%ofadultsareoverweightorobese[8],and
almosthalfofItalianmenandabout1of3Italianwomenare
overweight or obese [9].
The excess of adiposity is an established risk factor
for the development of cardiovascular diseases, type 2 dia-
betes, and hypertension, all characterized by resistance to
insulin-mediated glucose disposal. Insulin resistance and
the compensatory hyperinsulinemia associated with insulin
resistance have been shown to be independent predictors of
allthreeclinicalsyndrome[10].Severalstudieshavereported
that obesity, generally deﬁned as a body mass index BMI >
30, increases the risk of disease and all-cause mortality and
reduces life expectancy [11]. Caucasian individuals, who
reached a BMI > 40 between the ages of 20–29 years, could
expect a reduction in remaining years of life expected by
approximately 6 and 12 years, respectively [11, 12]. Obesity
has not only been linked to reduced life expectancy but
also to accelerated aging, as demonstrated by obese women
having telomeres that were 240bp shorter compared to lean
women of similar age [13].
Many factors inﬂuence the onset of obesity, including
genetic, environmental, socioeconomical, behavioral, and/or
psychological factors. The main cause that leads to the devel-
opmentofobesityisapositiveenergybalance,whichconsists
in imbalance between energy intake and expenditure, lasting
for several years. Such a balance is regulated by a complex
network of signals that connect the endocrine system with
the central nervous system [14]. Overnutrition, leading to
obesity, impairs systemic metabolic homeostasis and is a
metabolic stressor associated with intracellular organelles
(e.g., the endoplasmic reticulum) stress. Starvation and
malnutrition can impair immune function too [15].
Diﬀerentkindsofstressors,includinglifestressfulevents,
on the other hand, have been particularly linked to develop-
ment of visceral obesity [16]. The hypothalamic-pituitary-
adrenal axis and the central and peripheral components
of the autonomic nervous system constitute the two main
vital stress-system functions [5]. States of over- or under-
nutrition may impair the crosstalk between metabolic and
immune system, leading to the activation of the immune
response and the development of a “low-grade systemic
inﬂammation,” as conﬁrmed by increasing circulating levels
of proinﬂammatory cytokines, adipokines and other inﬂam-
matory markers detected in obese subjects. Activation of
the immune response in obesity is mediated by speciﬁc
signaling pathways, with Jun N-terminal kinase and IkappaB
kinase beta/nuclear factor kappa-light-chain-enhancer of
activated B cells being the most studied. It is known that
the above events modify insulin signaling and result in the
development of insulin resistance [16].
2.1. Visceral Fat (VF) and Subcutaneous Fat (SF). Increased
body mass induces the formation of fat deposits in the
visceral and subcutaneous structures [12]. Fat tissue is at
present considered as an active endocrine organ with a high
metabolic activity. It produces several mediators that are
important in metabolism (adipokines) and inﬂammation
(cytokines). Many of these cytokines also referred to as
“adipokines,”includingleptin,TNF-α,IL-6,heparin-binding
epidermalgrowthfactor(HB-EGF),andvascularendothelial
growth factor (VEGF) among others, may play an important
role in many diseases by promoting angiogenesis, inﬂamma-
tion, cell proliferation and insulin resistance [12].
Activation of proinﬂammatory pathways and secretion
of cytokines such as interleukin-6 (IL-6), plasminogen-
activator inhibitor-1, and free fatty acids (FFA) have been
suggested to produce insulin resistance [17, 18]. Fat accumu-
lation in the abdominal area is considered one of the main
risk factors for developing cardiovascular and metabolic
diseases. This eﬀect is probably depending on cytokines
synthesized by visceral adipose tissue and released into the
portal circulation, thereby reaching the liver, where they can
triggeraseriesofinﬂammatoryevents,includinggreaterFFA
and glycerol release [19]. In particular the proinﬂammatory
cytokine IL-6 regulates hepatic protein synthesis by evoking
an acute phase response such as C-reactive protein (CRP) or
serum amyloid-A. As reported by Libby and colleagues, the
QuebecHeartStudyhasshownthatobesityisassociatedwith
systemic inﬂammation, since there is a correlation between
VFandthelevelsofCRP[20].Studiesinrodentsandhumans
haverevealedthatbodyfatdistribution,includingVF,SF,and
ectopicfatiscriticalfordeterminingtheriskposedbyobesity
[21].
VF secretes more cytokines than subcutaneous adipose
tissue; in addition using either waist circumference and/or
waist-to-hipratioasaproxyofabdominalobesity,numerous
studies have found that VF is a stronger risk factor for
metabolic and cardiovascular diseases than body mass index
(BMI)orotherfatdepots.Adiposetissuecanproduceseveral
modulators of inﬂammation. This condition promotes the
development of diabetes mellitus (DM) which is accom-
panied by an increased risk of both macrovascular and
microvascular disease. The negative impact of obesity on
cognitive function may be, at least in part, due to vascular
defects, impaired insulin metabolism and signaling pathway
or a defect in glucose transport mechanisms in brain. It is
plausible to hypothesise that increased vascular dysfunction
at the level of the brain may in turn aﬀect memory function
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In a study performed on male C57BL/6 mice fed a
standard diet low in fat until the age of 6 weeks and then
switched to a high fat diet for the following 15 or 21
weeks, it has been shown that obese mice exhibited a higher
concentration of macrophages in visceral adipose tissue
compared to lean animals [23].
VF is associated with a low-grade inﬂammation due
to the increased secretion of numerous pro-inﬂammatory
cytokines from adipocytes and their associated macrophages
[12]. In this connection, our previous results showed that
in obese children, the presence of a chronic low-grade
inﬂammation corresponds to a shift to Th1-cytokine proﬁle
dominated by the production of IFN-gamma, accompanied
by insulin resistance [24]. However, the molecular basis
for the association between obesity and low-degree chronic
inﬂammation is still unknown.
2.2. AD Can Be Considered a Metabolic Disease. Diabetes
mellitus (DM) is a risk factor for nongenetic AD. Recent
studies in humans indicate that insulin signaling is impaired
in the AD brain [25]. Insulin is the hormone in charge of tis-
sutal glucose uptake, it binds to speciﬁc receptors expressed
on cell membranes and triggers the phosphorylation of
cellular substrates. A switch from a tyrosine phosphorylation
to a serine phosphorylation of the insulin receptor substrate
(IRS) family of proteins impairs the metabolic activity of
insulin leading to insulin resistance and type 2 diabetes. This
alteration may be mediated by stress and inﬂammation, as
shown by the eﬀects of cytokines released by immune cells.
Insulin receptors and insulin-sensitive glucose transporters
have been detected at the level of the medial temporal region
of the brain that supports memory formation, leading to
hypothesize that insulin may be involved in maintaining
normal cognitive function [22]. Moreover, AD is associ-
ated with cerebrovascular amyloid angiopathy in which
an increased expression of RAGE (receptor for advanced
glycation endproducts) was detected. Carbohydrate-derived
advanced glycation endproducts (AGEs) have been impli-
cated in the chronic complications of DM and have been
reported to play an important role in the pathogenesis of
AD [26]. They have been localized in AD brain and their
presence was shown to be signiﬁcantly increased in human
post-mortem samples of AD with diabetes compared to AD
without diabetes or nondemented controls [27]. RAGE has
been found to be a speciﬁc cell surface receptor for amyloid
β, thus potentially facilitating neuronal damage [28, 29].
A recent paper by de la Monte [30] discusses the
direct relationship between impaired insulin/IGF signaling,
increased amyloid-β precursor protein (AβPP) synthesis,
and the increased accumulation of Aβ peptide in amyloid
plaques, promoting neurodegeneration. The mechanism
proposed by de la Monte is that brain insulin deﬁciency
and resistance cause neuronal death due to trophic factor
withdrawal, deﬁcits in energy metabolism, and inhibition of
insulin-responsive gene expression, including those required
for acetylcholine homeostasis. It is known that insulin resis-
tance increases with age and that normal blood glucose levels
are maintained until the body is able to provide an adequate
amount of insulin (hyperinsulinemia). As described above,
peripheralinsulinresistanceismediatedbytheinﬂammatory
process that takes place within adipose tissue, enlarging
abdominal fat in obese individuals. As a matter of fact,
insulin resistance is a common ﬁnding in chronic inﬂamma-
tory diseases and, in particular, it is believed that increased
adipose-derived inﬂammatory cytokines induce a chronic
inﬂammatory state that not only increases cardiovascular
risk, but also antagonizes insulin signaling and mitochon-
drial function thereby impairing glucose homeostasis [31,
32].
2.3. Energy Metabolism Dysregulation. The decreased energy
metabolism due to insulin resistance ﬁrst and then to
reduced glucose uptake impairs ATP production. Chronic
inﬂammation, such as detected in obesity and stress condi-
tions, implies a constant, although low-grade, activation of
the immune system, as evidenced by the increased serum
levels of proinﬂammatory cytokines in subjects suﬀering
from chronic inﬂammatory diseases. In this connection,
Straub et al. [33] reported that neuroendocrine pathways
are involved in energy regulation: inﬂammation induces an
increase in cortisol serum levels, by stimulating HPA axis
and sympathetic nervous system(SNS), ending with sickness
behavior, characterized by strong reduction of muscle, brain,
and gut activity. Fat gain depends, inter alia, on a lack of
physical activity which brings to muscle loss and increased
leptin levels which, in turn, support muscle loss and fat
gain, leading to cachectic obesity [33]. In this respect it is to
remind that proinﬂammatory cytokines can disturb insulin
receptor and IGF-1 receptor signaling [34] and that FFA
induce insulin resistance [35].
As a result, insulin resistance produces a dysregulation
of energy balance at the level of liver, adipose tissue, and
muscle and, at the same time, favours the activated cells
of the immune system since they do not become insulin
resistant. Leptin, whose release is increased following the
enlargement of fat, stimulates glucose uptake by immune
cells and therefore their metabolic activity. In this way
a vicious circle takes place, with a continuous release of
proinﬂammatory adipokines such TNF, IL-6, resistin and
leptin which contribute to maintain a chronic inﬂammatory
state. Several inﬂammatory pathways have been shown
to contribute to metabolic dysregulation at several levels,
among them the modulation of insulin signalling is perhaps
the most crucial, as it is a highly conserved and dominant
metabolic pathway in nutrient and energy homeostasis. In
addition to cytokines, many of the inﬂammatory signalling
pathways that inhibit insulin receptor signalling are directly
triggered by nutrients, such as circulating lipids. Other
inﬂammatory pathways are induced by organelle stress
owing to nutrient overload and processing defects and
result in metabolic stress. These complexes connections are
schematically depicted in Figure 1.
2.4. Obesity and Systemic Inﬂammation. Macrophage accu-
mulationandthesubsequentlocalinﬂammationarebelieved4 Current Gerontology and Geriatrics Research
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Figure 1: The complex and interconnected pathways linking stress, inﬂammation, obesity and energy metabolism.
to result in numerous metabolic dysfunctions that accom-
panyobesity,includingsystemicinﬂammation.Macrophages
and adipocytes are closely related and share many functions:
for example, they both secrete cytokines and can be activated
bypathogen-associatedcomponents,suchaslipopolysaccha-
ride (LPS) [36]. Preadipocytes have been shown to transd-
iﬀerentiate into macrophages, and transcriptional proﬁling
has suggested that macrophages and pre-adipocytes are
genetically related [37].
AD was recently added to the obesity-related diseases
taking into account the release of inﬂammatory cytokines
by activated macrophages in visceral adipose tissue. Several
recent studies prospectively assessed the predictive value of
elevated pro-inﬂammatory cytokines for the risk of develop-
ing AD in cognitively intact individuals or for aggravating
AD symptoms in patients who were already diagnosed
with the disease. Higher plasma levels of the inﬂammatory
marker α1-antichymotrypsin and IL-6 [38], as well as higher
spontaneous production of IL-1β or TNF-α by peripheral
blood mononuclear cells [39], were found to be associated
with increased future risk of AD in older individuals.
The Framingham Heart Study comprising male partici-
pants(agerange55–88years)followedupoveraperiodof18
years revealed that obesity had an adverse eﬀect on cognitive
performance[40]. In agreement with this ﬁnding, Osher and
Stern described that obesity may contribute to the reduction
of cognitive skills observed in AD [41].
In the otherwise healthy older population, the combi-
nation of expansive waist circumference or BMI, with high
systolic or diastolic blood pressure, was linked to a modest
decrease in performance on tests of motor speed, manual
dexterity, and executive function [42]. The association
appeared to be so profound that the risk for AD increased
by 36% for every BMI unit at the age of 70 years.
Crosstalk between lymphocytes and adipocytes can lead
to immune regulation. Adipose tissue produces and releases
a variety of proinﬂammatory and anti-inﬂammatory factors,
including the adipokines leptin, adiponectin, resistin, and
visfatin, as well as cytokines and chemokines, such as TNF-
α, IL-6, monocyte chemoattractant protein 1 (MCP-1), and
others. Proinﬂammatory molecules produced by adipose
tissue have been implicated as active participants in theCurrent Gerontology and Geriatrics Research 5
development of insulin resistance and increased risk of
cardiovascular disease associated with obesity [43].
2.5.Cytokines,AdiposeTissueandAD. Immunesysteminﬂu-
encescentralnervoussystemthroughthereleaseofcytokines
targetingdiﬀerentbraindistricts.Cytokinesmediatenotonly
immune response but also neuron functions and survival
[44]. They may originate from peripheral immune cells and
reach the CNS by crossing the blood-brain barrier or may
be directly produced within the CNS by neurons and glial
cells [45]. Cytokines bind to speciﬁc cytokine receptors on
neurons and glial cells thereby directly inﬂuencing brain
function. Two main clusters of cytokines have been recog-
nized, based on the speciﬁc T-helper cells producing them:
type 1 helper cells, generally engaged in cellular immune
response and type 2 helper cells involved in humoral
immunity.
Cytokines are commonly classiﬁed in two categories:
interleukin-1 (IL-1), tumor necrosis factor α (TNF-α),
interferonγ (IFNγ), IL-12, IL-18 and granulocyte-mac-
rophage colony stimulating factor (GM-CSF) are well char-
acterized as pro-inﬂammatory cytokines whereas IL-4, IL-
10, IL-13 and transforming growth factor-β (TGF-β)a r e
recognized as anti-inﬂammatory cytokines.
2.6. Adipokines. The family of adipokines is continuously
expanding and includes also INFγ, LIF (Leukemia Inhibiting
Factor) and chemokines such as the MCP-1 and MIP-1
(Macrophagic Inﬂammatory Protein-1). TNF-α is secreted
by the activated macrophages and by adipocytes and plays an
important role in the defence of the host from infections and
inthedevelopmentoftheTh-1subpopulations;itisinvolved
in the pathogenesis of autoimmune diseases such as the
multiple sclerosis, rheumatoid arthritis, and I type diabetes.
PatientsaﬀectedbyinsulinresistancepresentincreasedTNF-
α levels and mice with a TNF-α deﬁciency are protected by
the insulin resistance-induced obesity.
Leptin is a typical adipokine produced in proportion to
the amount of the body fat; indeed its levels are related to
BMI. It has been shown that there is a direct link between
leptin, leptin receptor, and activation of mTOR (mammalian
target of rapamycin) [46]. Leptin and nutrients (i.e., amino
acids and glucose) show pulsatile secretion in vivo and
living cells continuously adjust their gene expression in
response to the changing milieu that inﬂuences the energy
status into the cells and modulates cell growth, proliferation,
and diﬀerentiation. The maker of this mechanism is the
mammalian target of rapamycin (mTOR), an evolutionarily
conserved 289-kDa serine-threonine protein kinase that is
inhibited by rapamycin [47]. Within this context, it has
been hypothesized that leptin might act as an endogenous
“sensing” factor that could act as a critical link among
environment (availability of nutrients), metabolism, and
immune responses [48]. Pro-inﬂammatory activity of leptin,
that potentiates T helper 1 (Th1) immune responses, is
due to decreased Treg cell proliferation [49, 50]. Matarese
and colleagues showed that the leptin/mTOR signalling
pathway inﬂuences Treg cell responsiveness according to
the energy metabolism. High metabolic rate determines
Treg cell hyporesponsiveness sustained by mTOR activation,
whereas inhibition of mTOR with rapamycin enhances Treg
cell proliferation and their anti-inﬂammatory activity [47].
Leptin-mTOR overexpression in freshly isolated Treg cells
is responsible for their state of hyporesponsiveness. The
hypothesis that a metabolic control of immune-mediated
pathogenesis of obesity and obesity-related insulin resistance
exist [51, 52], has recently reinforced the concept that
metabolism and proliferation of lymphocytes can impact,
at diﬀerent levels, the control of inﬂammation, autoim-
munity, and immune-mediated disorders [48, 53]. In all
of these conditions, Treg cells have a high metabolic state,
high ATP and mTOR activity and are unresponsive to
regulatory action in immune/inﬂammatory response [54].
Blood leptin levels are directly correlated with adiposity
[55, 56]. In the presence of excessive food intake, aggra-
vated by psychological stress, the increase of leptin induces
activation of mTOR that determines adverse eﬀects on
age-related diseases and inhibition of autophagy in the
liver (lipophagy) which contributes to steatosis and lipid
accumulation in VF [57]. In the hypothalamus, leptin
inhibits food intake through mTOR activation, and mTOR
inhibition with rapamycin prevents leptin-induced anorexia
[58, 59].
In a condition of lack of food and consequent reduction
of the body fat mass, low levels of leptin lead to a reduced
metabolic waste to preserve the energy necessary to support
the functions of vital organs such as heart, kidney, and brain;
on the other hand, the ﬁnding of high levels of leptin in
obese subjects has been interpreted as the result of relative
leptin resistance at the level of nervous central system. As
explained before, although the eﬀects of leptin can favour
survivalinadverseconditionssuchasfast,itinducesimmune
alterations blocking the precursor of Treg in favour of the
Th17 clone. Adipocyte-derived IL-17 plays a crucial role in
the development of chronic inﬂammation, autoimmunity,
insulin resistance [60] and, in our opinion, in the promotion
of AD. Leptin interferes with insulin signalling and in type 2
diabetesplasmaleptinlevelswerefoundtobecorrelatedwith
the degree of insulin resistance; therefore, insulin resistance
syndrome is accompanied by hyperleptinemia as well as
hyperinsulinemia [61, 62]. In obese patients leptin and TNF-
α induce endothelial dysfunction and oxidative stress [63].
Only in body massoflean individuals leptin regulatesinsulin
action in the peripheral circulation, decreases brain beta-
s e c r e t a s el e v e l sa n dm o d u l a t e sA β turnover [64]. Severe
obesity is depending on a lack of leptin signalling due
to mutation of leptin itself (ob/ob) or the leptin receptor
(db/db) resulting in an increase of food intake concomi-
tant with a reduction of energy expenditure. The main
mechanisms of leptin resistance previously described are
(i) leptin failure to cross the blood-brain barrier because a
downregulation of leptin transporter (as LepRa or LepRe),
(ii) hypothalamic LepRb downregulation, (iii) abnormalities
in the leptin receptor signalling pathways, as inhibition
of the JAK2-STAT3 pathway, overexpression of SOCS-3,
impairment of PI3K-mTOR pathway or more recently of the
ERK pathway [59].6 Current Gerontology and Geriatrics Research
So therefore, hyperleptinemia is a sign of leptin-re-
sistance and this leptin resistant state was associated with
impaired activation of the PI3K/AKT pathway and a hyper-
stimulation of mTOR pathway [65].
As mentioned before, VF secretes more cytokines than
subcutaneous adipose tissue and as obesity takes place, sev-
eral proinﬂammatory factors in adipose tissue are produced.
Moreover, adipocytes size is an important determinant of
leptin synthesis, since larger adipocytes contain more leptin
than smaller ones [66]. Therefore, summarizing we can
say that local inﬂammation triggered by macrophage accu-
mulation results in numerous metabolic dysfunctions that
accompany obesity and bring to the development of systemic
inﬂammation [67]. As evidenced by the work of De Rosa et
al. [50] high levels of leptin put Treg cells in an anergic state,
leadingtotheactivationofTh1cellsandthereleaseofseveral
inﬂammatory mediators with a development of that chronic
inﬂammatory state repeatedly reported in obese patients.
As outlined before, though the portal circulation the
cytokines reach the liver, where they can stimulate hepatic
inﬂammation thereby inducing a chronic systemic inﬂam-
matoryresponseandreleaseoftoxicFFA.FFAhavelongbeen
known to produce deleterious eﬀects on pancreatic beta-
cell function inhibiting insulin production and inducing
insulin resistance [68] whereas in parallel proinﬂammatory
cytokines, such as TNF-α, alter insulin receptors [69].
2.7. Adipokines and AD: Protective Role of Leptin. Recent
reports have shown that in addition to its action on the
hypothalamus, leptin may also exert its eﬀect on the cortex
and on the limbic areas, which are involved in cognitive and
emotional regulation of feeding behavior [70].
Leptin roles on brain structure and function are being
extensively characterised by studies showing that human
brain is highly neuroplastic and depends on leptin for
its proper development. Additional studies in diﬀerent
populations need to conﬁrm the role of leptin as a biomarker
for neurodegenerative diseases.
Some evidence links adipokines directly to cognition.
The adipoinsular axis—with leptin and insulin as its main
components—has central roles on the regulation of brain
function [71]. Leptin regulates food intake and energy
metabolism binding to speciﬁc regions of the hypothala-
mus. Recently it has been shown that leptin has extra-
hypothalamic eﬀects that may protect the brain against
the development of mood and neurodegenerative disorders,
suchasAD[70,72].Leptinappearstoexertimportanteﬀects
on brain development as leptin-deﬁcient rodents display
abnormal brain development and leptin actively participates
in the development of the hypothalamus [73] and in the
processes of learning and memory, especially during aging:
it was actually described a speciﬁc eﬀect in the CA1 region
of the hippocampus, selectively altered in AD [74]. Leptin
is a potent neurogenic factor not only to hippocampal but
also to cortical neurons [75] and has neuroprotective actions
against glutamatergic cytotoxicity and oxidative stress [76].
Inaddition,leptinwasshowntopromotetheproliferationof
neuronal precursors as observed following intracerebroven-
tricular administration of a lentiviral vector encoding leptin.
After 3 months of treatment the number of proliferating
hippocampalcellswasincreased,asjudgedbymorphometric
analysisandbytheattenuationofAβ-inducedneurodegener-
ation [77]. By decreasing the accumulation of intraneuronal
lipids, leptin suppresses amyloidogenic pathways. In addi-
tion, by inhibiting GSK-3b (the most relevant tau kinase),
leptin reduces protein tau phosphorylation, inhibiting the
formation of neuroﬁbrillary tangles. The inhibitory eﬀects of
leptin on the formation of senile plaques and neuroﬁbrillary
tangles seem to be mediated by the selective activation of
AMPK in neurons. Leptin was previously shown to reduce
the amount of extracellular Aβ,b o t hi nc e l lc u l t u r ea n d
animal models and its chronic administration resulted in
a signiﬁcant improvement in the cognitive performance of
transgenic animal models [78]. In AD, weight loss often pre-
cedes the onset of dementia and the level of circulating leptin
is inversely proportional to the severity of cognitive decline.
It is speculated that a deﬁciency in leptin levels or function
may contribute to systemic and CNS abnormalities leading
to disease progression. Furthermore, leptin deﬁciency may
aggravate insulin-controlled pathways, known to be aberrant
in AD [78]. As a matter of fact, signiﬁcantly lower plasma
levels of leptin in AD patients compared to the controls were
detected [79].
More recently, low leptin levels have been implicated as a
direct cause of cognitive impairment, particularly AD [79].
In that case, the absence of beneﬁcial eﬀects of leptin in
the central nervous system would predispose to cognitive
impairment. However, the protective eﬀect of leptin against
the development of AD was observed only among lean
individuals; on the contrary obese humans, despite having
high leptin levels, may not beneﬁt from protective eﬀects
of leptin because of central leptin resistance. In this way a
paradoxical situation takes place: leptin is a neuroprotective
factor,counteractingADcognitiveimpairment,asconﬁrmed
by the clinical observation that a weight loss precedes AD
manifestations and is accompanied by reduced serum levels
of leptin. On the other hand, obese patients exhibit high
levels of leptin that cannot perform their protective eﬀects
since leptin resistance has been induced at the level of
CNS. Other studies are needed to elucidate the molecular
mechanisms promoting leptin resistance.
2.8. Insulin Resistance in AD. Brain glucose metabolism was
f o u n dt ob ei m p a i r e di nA D[ 80] and the Rotterdam study
and others that followed [81, 82] established that type 2
diabetes mellitus increases the risk for developing cognitive
impairment and dementia in AD. In that case, insulin resis-
tanceandlowinsulinlevelsintheCNS(interestinglyreferred
as “diabetes of the brain’’) would lead to the accumulation of
Aβ and cognitive impairment. Cerebrovascular and central
inﬂammation would contribute further to the pathogenesis
of AD [72, 83]. As reported by H¨ olscher in 2011 [84], a
common observation for type 2 diabetes and AD is the
desensitization of insulin receptors in the brain. Insulin acts
as a growth factor in the brain and shows neuroprotectiveCurrent Gerontology and Geriatrics Research 7
properties, activating dendritic sprouting, regeneration, and
stem cell proliferation. The impairment of growth factor
signalling such as early insulin receptor desensitization has
been suggested to be involved in the cascade of neurode-
generative events leading to AD [80, 84]. Recently animal
models that reﬂect the pathologic conditions of both type
2 diabetes and AD, were generated. APP23 transgenic mice,
a well-established animal model for AD were crossed with
ob/ob mice or polygenic NSY mice, as a model for diabetes.
Taking advantage of this experimental model, it has been
demonstrated that a diabetic condition enhances cognitive
dysfunction with cerebrovascular changes such as vascular
inﬂammation and cerebral amyloid angiopathy and that
neuropathological changes are associated with impairment
of brain insulin signaling [83].
In addition, low insulin levels and insulin resistance can
contribute to a decrease in acetylcholine levels, which repre-
sents a possible biochemical link between diabetes mellitus
and AD [85, 86].
Human and experimental animal studies revealed that
neurodegeneration associated with peripheral insulin resis-
tance is likely mediated via a liver-brain axis whereby toxic
lipids, including ceramides, cross the blood brain barrier
and cause brain insulin resistance, oxidative stress, neuroin-
ﬂammation, and cell death [87]. Recent evidence demon-
strates that sphingolipid metabolism is dysregulated in
obesity and speciﬁc sphingolipids may provide a common
pathway that link excess nutrients and inﬂammation to
increased metabolic and cardiovascular risk [88]. Insulin
resistance promotes lipolysis, and lipolysis generates toxic
lipids, that is, ceramides, which further impair insulin sig-
nalling,mitochondrialfunction,andcellviability[89].Cyto-
toxic ceramides cause insulin resistance by activating pro-
inﬂammatory cytokines and inhibiting insulin-stimulated
signalling through PI3 kinase-Akt [90].
2.9. Stress and Leptin. As described above, we may argue
that obesity itself is a known risk factor for AD, especially
in the presence of psychological stress. It is well known
that people with depression, especially older adults, have
reduced cognitive performance. In addition, many people
with dementia also have depression. This illness is associated
with elevated levels of cortisol and cytokines which may
directly damage the hippocampus and increase the risk of
dementia and depression [6, 91]. Depression is frequently
a prodrome of dementia and the incidence of depression
among patients with AD is estimated to be greater than 40%
[92].
Social stressors have eﬀects on food intake and adiposity
and, in this case, the individuals with psychological stress
have elevated plasma insulin and leptin concentrations com-
pared to nonstressed humans [93]. Glucocorticoids (GC)
and insulin interact in the upregulation of serum leptin con-
centrations. In presence of psychological chronic stress GC
lead to overeating and to obesity in spite of elevated leptin
concentrations [94]. When the stressor is viewed as a threat
without resources to change the coping well with, the stress
response is the HPA axis activation and it is a potent trigger
ofcortisolrelease[95].Socialstressorshavevariouseﬀectson
foodintakeandadiposity:forexamplesubordinateratsshow
elevated plasma insulin and leptin concentration compared
todominantanimals[96].IncreasedGCconcentrationshave
been associated with VF accumulation and with insulin
r e s i s t a n c ea sw e lla sl e p t i nr e s i s t a n c e[ 97]. In humans, the co-
elevation of insulin and cortisol is depending from comfort
food preference (high fat and sweet food). Palatable comfort
food promotes dependence activating brain reward system
comprisingopioids,dopamineandendocannabinoid.Leptin
resistance produces impaired “brake” that in part explain the
epidemic “globesity” of eating without metabolic need [98].
The relationship between stress and food intake in humans
may also involve eﬀects of GC on NPY, CRH, leptin as well
as opioids. It is worthwhile to note that GC receptor density
is increased in VF compared to SF and stimulates lipolysis in
the whole body [99, 100].
Cortisol increase in presence of insulin inhibits lipid
mobilization and promotes the diﬀerentiation and pro-
liferation of adipocyte. Increased GC concentration has
been associated with insulin and leptin resistance. Those
adiposity signals play a role not only in energy regulation
but also on the brain reward system by continued search
for additional comfort food [101]. Stress-induced cortisol
exposure may impair right prefrontal cortex activity, thus
impeding the more reﬂective cognitive control over eating
[102]. Therefore, leptin stimulation caused by GC promotes
“leptinresistant”obesityand,inturn,obesitymaycontribute
to the reduction of cognitive skills observed in AD. Results
from other published studies demonstrate an association
of obesity with deﬁcits in learning, memory, and executive
functioning in human patients [103, 104]. This relationship
betweenobesityandcognitiveimpairmenthasalsobeendoc-
umented in experimental animals [105–107]. Collectively,
results from the study of Pistell and colleagues reinforce the
link between diet-induced obesity and cognitive loss and
suggest potentially causal roles for high levels of dietary
fats and increased brain inﬂammation in driving obesity-
induced cognitive disruption [108].
Prolonged exposure to proinﬂammatory cytokines
impairs synaptic plasticity, contributing to cognitive and
mood disorders [109]. TNF-α and IL-1β, whose receptors
are speciﬁcally present at the level of hypothalamus,
hippocampus and cortex, were shown to impair neuronal
plasticity.
Notably, recent collective reports indicate that after brain
injury and in neurodegenerative disorders neurogenesis is
controlled by cytokines, chemokines, neurotransmitters, and
reactive oxygen/nitrogen species (ROS), which are released
b yd y i n gn e u r o n sa sw e l la sb ya c t i v a t e dm a c r o p h a g e s ,
microglia, and astrocytes [110].
2.10. Age-Related Conditions That Can Be Largely Prevented
or Delayed by Lifestyle Interventions
2.10.1. Nutritional and Dietary Factors. The studies reported
above strongly suggest that alterations of energy metabolism
in favor of VF accumulation promote insulin resistance and8 Current Gerontology and Geriatrics Research
achronicinﬂammatorystatuswhichhavebeenrecognizedas
important cofactors in AD initiation and progression. From
this, it follows that a preventive strategy should include a
reduction of abdominal fat deposits, through a proper nutri-
tion tailored to the individual needs. [12]. Great importance
in this respect are showing the modern technologies for
analysis of body composition that determine fat mass, fat
free mass, total body water, intra- and extracellular water,
mineral, metabolism and inﬂammatory status in the body
(BIA-ACC and TomEEx devices) [111, 112]. In fact, thanks
to these noninvasive and low cost technologies, it is possible
to acquire information on the above parameters and follow
up the changes induced in the low level inﬂammatory status
secondary to modiﬁcations in lifestyle, especially in diet and
physical activity [113–115].
Several follow-up studies have already reported that
decreased AD risk is associated with increasing dietary or
supplementary intake of antioxidants (e.g., vitamins E and
C, fruits and vegetables). A diet high in antioxidants may
reduce inﬂammation, which is associated with the risk of
dementia [92]. A variety of dietary supplements have been
reported to be beneﬁcial for learning in animals and humans
[116]. Positive eﬀe c t so nb r a i nf u n c t i o nh a v eb e e nr e p o r t e d
for ﬁsh oil, teas, fruits, folate, spices, and vitamins [117].
Particularly interesting are plant-derived products such as
grapes, blueberries, strawberries, tea, and cocoa, which
beneﬁt memory in rodents [118]. Furthermore, studies
found that higher adherence to “Mediterranean diet” (i.e.,
a dietary pattern with higher intake of ﬁsh, fruits, and
vegetables rich in antioxidants) produced beneﬁcial eﬀectsin
AD patients. On the contrary diets enriched with saturated
fats and cholesterol increase the risk, which is reversed by
polyunsaturatedfattyacidsandﬁsh.Fattyacidsmayalsoplay
a part in the synthesis and ﬂuidity of nerve cell membranes,
insynapticplasticityandneuronaldegeneration.Inaddition,
oxidative stress is one of the central features in the AD brain.
Thus, it may be plausible that supplementation or diet rich
in antioxidants such as fruits, vegetables, and vitamins E and
C might protect against AD.
B vitamins were particularly investigated in clinical
studies with the attempt to deﬁne an association between
serum levels of these vitamins and the risk of dementia and
AD and diﬀerent intervention trials were made obtaining,
unfortunately, discordant results. As a matter of fact, the
Cochrane systematic review concluded that folic acid and
vitamin B12 supplementations have no beneﬁts on cog-
nition, although folate plus vitamin B12 are eﬀective in
reducing plasma homocysteine.
Folate (vitamin B9), vitamin B12, and vitamin B6 are
cofactors in the reactions responsible for homocysteine
(Hcy) transformation and removal in the “so called” one-
carbon metabolism [119]. Plasma levels of these three vita-
mins are therefore strictly related to Hcy levels; according to
a general paradigm, high plasma Hcy (hyperhomocysteine-
mia, HHcy) is related to low B vitamin levels. After many
studies in humans and in animal models, it is now accepted
that moderate HHcy is a potential risk factor for AD,
although the possibility that it represents just a marker of
the process exists, the association of low B vitamins with
AD is still more controversial [120]. However, the majority
of retrospective studies evidenced increased Hcy levels in
AD subjects and prospective studies pointed out that HHcy
is evident before AD development, stressing the idea of a
causative function of HHcy in AD [121].
On the basis of these considerations, few interventional
studies were performed to evaluate the potentially beneﬁcial
supplementationwithBvitaminsintheattempttolowerHcy
levels and improve cognitive functions. Only one of these
studies demonstrated that Hcy-lowering intervention was
associatedtotheimprovementoftheeﬀectsofcholinesterase
inhibitors therapy; other studies demonstrated that B vita-
min supplementation was able to reduce Hcy levels but
did not improve cognitive status or delay cognitive decline
[122]. The apparent controversial results obtained after
observational and interventional studies in AD patients
are probably due to undisclosed biases and methodological
troubles occurring in the design of these protocols. Firstly,
the most evident (as well as incomprehensible) aspect of
the interventional studies on B vitamin supplementation
conducted so far is that subjects recruited for the trials
had normal Hcy levels; in some case, HHcy was among
exclusion criteria. We should suppose that individuals with
normal Hcy levels do not present any alteration in one-
carbon metabolism; therefore, B vitamin supplementation
can very unlikely result in evident beneﬁcial eﬀects. The
second aspect to be taken into account is the duration of the
trial, since quite short treatments were done in some of these
studies. Moreover, the high variability in the doses used for
the B vitamin supplementation makes diﬃcult to compare
the results obtained from diﬀerent trials. Finally, appropriate
(sensitive) cognitive tests able to reveal subtle diﬀerences and
larger (more variable) populations could improve the results
of the interventional trials with B vitamins supplementation
in AD.
2.10.2. Physical Activity. The risk for dementia and AD was
also increased in older people with increasing social isolation
and less frequent and unsatisfactory contacts with relatives
and friends. In fact several studies indicate that a poor social
network or social disengagement is associated with cognitive
decline and dementia. Rich and large social networks also
provide aﬀective and intellectual stimulation that could
inﬂuence cognitive function and diﬀerent health outcomes
through behavioral, psychological, and physiological path-
ways [123].
It has also been shown that low-intensity activity such
as walking may reduce the risk of dementia and cognitive
decline and experimental studies in animal models have
established a direct correlation between physical exercise and
neurogenesis, especially in the hippocampus [124]. Physical
activity is important also in promoting brain plasticity, and
it may also aﬀect several gene transcripts and neurotrophic
factors that are relevant for the maintenance of cognitive
functions. A strong protective eﬀect of regular physical
activity in middle age against the development of dementia
and AD in late life was reported, especially for persons with
the APOE4 allele.Current Gerontology and Geriatrics Research 9
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So regular exercise and intellectual stimulation may
represent those useful mild stresses that should stimulate
maintenance and repair pathways and cause adaptation of
cells and the ability to tolerate stronger stresses [125].
An important role in inﬂuencing the life span has been
attributed to the tissue pH which is related to the metabolites
of various nutrients. In a recent study dealing with the
yeast chronological life span model it has been shown that
acidiﬁcation of the medium accelerates yeast aging [126].
A central player of this eﬀect has been identiﬁed by TOR
pathway: when the cell cycle is blocked but mTOR is still
active, it causes hypertrophic, hyperactive, hyperfunctional
phenotype, with compensatory resistance to signals such
as insulin and growth factors, switching quiescence into
senescence; therefore, TOR limits life span by accelerating
age-related diseases [125]. By contrast, the deletion of either
TOR1 or SCH9/S6K seems to extend yeast chronological
life span in part by depleting ethanol and acetic acid [127].
TheseupdatessupporttheimportantroleoftissuepH,which
should not be acidiﬁed by foods high in protein (meat,
cheese). “Anti-inﬂammatory” foods, such as diets rich in
fruits and vegetables, may prevent osteopenia and cachectic
obesity with an important buﬀer action and possibly at
negative PRAL (potential renal acid load).
3. Conclusion
The schematic diagram (Figure 2) illustrates our suggested
link between stress, obesity, and Alzheimer’s Disease. At the
center of the system a series of events, that begin and are
maintained by psychosocial stress, trigger the inﬂammation
due to immunological dysregulation that arises from dys-
metabolic processes caused by high energy intake.10 Current Gerontology and Geriatrics Research
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